EUVIMEDEUVIMED entdecken
Crossref

Cilostazol for Major Depressive Disorder After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial

Parisa Rajabi, Fateme Taghavi Zanjani, Mohamadjavad Ershadmanesh, Faezeh Mokhtari, Zahra Haji Faraj Tabrizi, Melika Jameie, Saeed Natheghi, Maryam Mehrpouya, Sara Hashempour, Sayedeh Elham Sharafi, Hamed Vahidi, Ahmad Shamabadi und 2 weitere

Research in Heart Yield and Translational Medicine (RHYTHM) · 08.09.2026

DOI: 10.18502/rhythm.v21i3.22566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research in Heart Yield and Translational Medicine (RHYTHM), online erschienen am 08.09.2026. Verfasst von Parisa Rajabi und 13 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Major depressive disorder (MDD) frequently occurs alongside coronary artery disease (CAD), worsening cardiovascular outcomes. Cilostazol is a phosphodiesterase 3 inhibitor used as an antiplatelet agent with potential antidepressant effects. This study evaluated the efficacy of cilostazol for treating depressive symptoms in participants with CAD.

Methods

This 6-week, double-blind, placebo-controlled clinical trial enrolled individuals with MDD and Hamilton Depression Rating Scale (HDRS) scores of 14 to 17 who had undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Participants were randomly assigned to receive cilostazol (100 mg/d) or placebo. Outcomes included HDRS scores and adverse events.

Results

Baseline characteristics were similar between the groups (all P>.05). A significant time × treatment interaction effect on HDRS scores was observed (P=.037; partial η2=0.055). The cilostazol group showed greater reductions in HDRS scores through weeks 4 and 6 (P=.012 and P=.054, respectively). Adverse effects were not serious and were comparable between the groups (all P>.05).

Conclusion

Cilostazol was beneficial and safe for treating depressive symptoms in individuals who had recently undergone PCI or CABG. Further studies are needed to support broader clinical application

Zitieren

APA

Rajabi, P., Zanjani, F. T., Ershadmanesh, M., Mokhtari, F., Tabrizi, Z. H. F., Jameie, M., Natheghi, S., Mehrpouya, M., Hashempour, S., Sharafi, S. E., Vahidi, H., Shamabadi, A., Noorbala, A., & Akhondzadeh, S. (2026). Cilostazol for Major Depressive Disorder After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial. Research in Heart Yield and Translational Medicine (RHYTHM). https://doi.org/10.18502/rhythm.v21i3.22566

Vancouver

Rajabi P, Zanjani FT, Ershadmanesh M, Mokhtari F, Tabrizi ZHF, Jameie M, et al. Cilostazol for Major Depressive Disorder After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial. Research in Heart Yield and Translational Medicine (RHYTHM). 2026. doi:10.18502/rhythm.v21i3.22566

BibTeX
@article{Rajabi2026,
  author = {Rajabi, Parisa and Zanjani, Fateme Taghavi and Ershadmanesh, Mohamadjavad and Mokhtari, Faezeh and Tabrizi, Zahra Haji Faraj and Jameie, Melika and Natheghi, Saeed and Mehrpouya, Maryam and Hashempour, Sara and Sharafi, Sayedeh Elham and Vahidi, Hamed and Shamabadi, Ahmad and Noorbala, Ahmad-Ali and Akhondzadeh, Shahin},
  title = {Cilostazol for Major Depressive Disorder After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {Research in Heart Yield and Translational Medicine (RHYTHM)},
  year = {2026},
  doi = {10.18502/rhythm.v21i3.22566}
}
Kostenlos starten →